Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Its lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. Ocaliva is approved in the US and the EU for use in primary biliary cholangitis.


Company Growth (employees)
Type
Public
HQ
New York, US
Founded
2002
Size (employees)
456 (est)
Intercept Pharmaceuticals was founded in 2002 and is headquartered in New York, US

Key People/Management at Intercept Pharmaceuticals

Mark Pruzanski

Mark Pruzanski

Chief Executive Officer & President
Luciano Adorini

Luciano Adorini

Chief Scientific Officer

Intercept Pharmaceuticals Office Locations

Intercept Pharmaceuticals has offices in New York, Wien, Gouda, Mississauga and in 8 other locations
New York, US (HQ)
10 Hudson Yards
Zürich, CH
1 Kalanderpl.
Madrid, ES
135 Paseo de la Castellana
Lisboa, PT
Centro Empresarial Torres de Lisboa Rua Tomás da Fonseca, Torre G, 1º Piso
Milano, IT
6 Largo Francesco Richini
London, GB
2 Pancras Rd
Show all (12)

Intercept Pharmaceuticals Financials and Metrics

Intercept Pharmaceuticals Financials

Intercept Pharmaceuticals's revenue was reported to be $25 m in FY, 2016
USD

Revenue (Q2, 2017)

30.9 m

Gross profit (Q2, 2017)

30.6 m

Gross profit margin (Q2, 2017), %

99%

Net income (Q2, 2017)

(86.6 m)

EBIT (Q2, 2017)

(80.5 m)

Market capitalization (13-Nov-2017)

1.5 b

Cash (30-Jun-2017)

62 m

EV

1.8 b
Intercept Pharmaceuticals's current market capitalization is $1.5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

25 m

R&D expense

153.9 m

General and administrative expense

273.6 m

Operating expense total

427.5 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

5.5 m5.2 m21 m30.9 m

Cost of goods sold

97 k279 k

Gross profit

21 m30.6 m

Gross profit Margin, %

100%99%
USDY, 2009Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

4.4 m15.4 m17.7 m45.5 m13.4 m20 m32.7 m43.7 m

Accounts Receivable

9.1 m

Inventories

2.7 m6.1 m13.6 m2.3 m

Current Assets

147.6 m245.8 m641.7 m707.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

33.5 m11.2 m45 m18.1 m104.4 m88.3 m72.4 m49.2 m51.7 m105.2 m67 m62 m

Accounts Receivable

10.6 m13.2 m

Inventories

2.1 m2.7 m

Current Assets

158.4 m138.9 m306.6 m279.1 m410.4 m741 m702.5 m574.9 m505.3 m794.6 m635 m578.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(67.8 m)(283.2 m)(226.4 m)(412.8 m)

Depreciation and Amortization

105.7 k442.8 k1.7 m3.8 m

Accounts Receivable

(9.1 m)

Inventories

(1.7 m)(2.3 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(31.7 m)(257.7 m)33.5 m(35.8 m)(39.4 m)(47.9 m)(50.9 m)(126.7 m)(77.3 m)(88.8 m)(89.9 m)

Accounts Receivable

10.6 m

Inventories

2.1 m
USDY, 2017

EV/EBIT

-22.4 x

Revenue/Employee

67.7 k

Financial Leverage

3.6 x
Show all financial metrics

Intercept Pharmaceuticals Market Value History

Intercept Pharmaceuticals's Web-traffic and Trends

Intercept Pharmaceuticals Online and Social Media Presence

Intercept Pharmaceuticals Company Life and Culture

You may also be interested in